|
CD3-binding (T cell engaging) immune stimulating antibody-based therapies |
|
Enduring |
|
$25.00 |
|
Cytokine Release Syndrome (CRS) |
|
Enduring |
|
$25.00 |
|
Definition, history and application of immunosafety in drug development |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Gene Therapy |
|
Enduring |
|
$25.00 |
|
HESI Human health and Safety |
|
Enduring |
|
$0.00 |
|
HESI: Human Health and Safety |
|
Enduring |
|
$0.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Immuno-oncology |
|
Enduring |
|
$25.00 |
|
Immuno-oncology |
|
Enduring |
|
$25.00 |
Facebook
Twitter
LinkedIn
Forward